NHERF2 and cancer: Furthermore, we observed a significant reduction in the percentage of NHERF2 immunoreactive cancer cells in HPV16+ tumors, compared with well and moderately differentiated HPV− OPSCCs, suggesting the importance of 16E6’s targeting of NHERF2 in HPV-driven oncogenesis in the head and neck area.